Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Issues within maintenance therapy standardization in MM

Giada Bianchi • 15 Sep 2019
IMW 2019
Multiple Myeloma

Giada Bianchi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the financial and geographical implications of the availability of maintenance therapy drugs for multiple myeloma (MM), speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Giada Bianchi

First-in-human study of autologous memory-like NK cells in patients with MRD+ multiple myeloma 1:30
First-in-human study of autologous memory-like NK cells in patients with MRD+ multiple myeloma
Giada Bianchi • 29 Sep 2023
Novel laboratory-based therapeutic approach in AL amyloidosis: investigating FLC secretion 1:53
Novel laboratory-based therapeutic approach in AL amyloidosis: investigating FLC secretion
Giada Bianchi • 29 Sep 2023
Investigating the proteasome stress response as a potential novel therapeutic target in myeloma 1:48
Investigating the proteasome stress response as a potential novel therapeutic target in myeloma
Giada Bianchi • 29 Sep 2023
The impact of CHIP in patients with AL amyloidosis 1:52
The impact of CHIP in patients with AL amyloidosis
Giada Bianchi • 29 Sep 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals